Nanoscience Share Discussion Threads

[the drewster] 01/12/2007 13:59

My target for 1st June 2008 is now 35p, For June 2009 70p and for June 2010 £2. I genuinely believe this is the start of something very significant, and it will only become apparent just how big in the course of the next 18-24months. I will be holding and building in the interim, but already very heavily long here.

[spekky] 30/11/2007 17:19

Don't think the order was filled today,last time this happened it took untill tue for the large trade to appear.If the regulatory approvals follow quickly then todays sellers might just have some regrets.
IMHO today is just a bit "cart before horse" if you know what I mean,good to know that a "global" has seen fit to sign up with Toumaz before the clinical approvals are in place though.I guess from their perspective they've avoided a more costly auction process.

[spekky] 30/11/2007 12:15

Just listened to it,amazing stuff.......cheers.

EDIT, I think that todays announcement coupled with apparently little share price movement needs to be put into context.In a recent post I mentioned FDA/EURO approval for clinical trials ,until these are granted,and the trials are successful,todays announcement has little relevance. Those things represent the green light,at the moment we have n't moved to amber.

[the shuffle man] 30/11/2007 10:10

Excellent report they have some great ideas for the future lets hope no one else gets there first, the potential here is mind boggling.

[the shuffle man] 30/11/2007 10:03

Anyone invested in Nanos should listen to this report, its very informative and the potential at Toumaz is massive.

[the shuffle man] 30/11/2007 09:59

New generation of digital plaster to be released begining of 2008. They have a 5 year plan to create the artificial pancreas.

[spekky] 30/11/2007 09:57

Just realised I need to download "Realplayer" from the beeb,will have a listen later.....cheers.Might be worth PapalPower putting that link in the header (if time permits)

[the shuffle man] 30/11/2007 09:55

Just listening to it, very interesting explains how the technology works with respect to monitoring vital signs, including diabetes and kidney failure. Its well worth listening to.

[spekky] 30/11/2007 09:46

The Shuffle Man
Good find,unfortunately I can't listen to the programme,media player won't play it for some reason.

[the shuffle man] 30/11/2007 09:40

Just found this !!!





Digital Medicine

Science journalist Philip Ball looks at the dawn of a brave new era of medical technology that promises to revolutionise the way we receive health care.

Digital medicine aims to take health care out of the hospital and into the home using simple devices found in our mobile phones and home computers.

Philip visits Imperial College in London to talk to Professor Chris Toumazou and his colleagues at the Institute of Biomedical Engineering. Professor Toumazou is using wireless technology to monitor and treat patients without them having to set foot in a hospital.

One of these devices is a digital plaster that will allow doctors to monitor their patients' vital signs any time and from anywhere in the world. He's also working on an artificial pancreas that can monitor and supply insulin to someone with diabetes, in exactly the same way a healthy pancreas would, without the need for daily monitoring and uncomfortable injections.

The true frontier, however, is to combine a computer chip with DNA to create the ultimate in personalised healthcare, drugs that are designed and prescribed specifically to your body's needs.

Philip Ball talks to the team at Imperial and discovers whether a visit to the GP's surgery or hospital is about to become a thing of the past

[spekky] 30/11/2007 08:50

Too soon Don,MMs appear to be giving 0.35 above the bid if your prepared to sell.Dont forget that TW had Guy Spelman on recently and will be keen to crow.Other publicity will flow from this even if its just speculation as to who the partner is.The partner is "global" so you can take it that the future of Toumaz is assured and for those of us who worry about funding issues,that too,seems to be sorted.
I would guess there's a 250k to 300k buy order which has n't been filled yet and will of course appear as a sell when it does surface.
It will also be interesting to see how soon the directors adjust their personal holdings.

[don muang] 30/11/2007 08:24

>The Shuffle Man - 30 Nov'07 - 08:08 - 256 of 258
>This is still under the radar of most PIs

Given the lack of transactions showing in first 20 minutes of trading opening then ii certainly is under the PI's radar....I thought there might be a few who had it on watchlist and would have jumped in after RNS - but obviously not..... or am I 'speaking' too soon........

[spekky] 30/11/2007 08:16

My guess would be that its Medtronic but it could be a long time before it becomes certain,however I'll take any of the others that Chris Toumazou mentions in his recent speech (see link post 247 read p25 to p38).

[humbugg] 30/11/2007 08:11

drewster,
well we didnt have to wait to long. great news, funding in place, first of many. lets hope its reflected in the market.

[the shuffle man] 30/11/2007 08:08

This is still under the radar of most PIs top up whilst you can dont think we will see this price for much longer

[the shuffle man] 30/11/2007 08:05

Good announcement i wonder who the strategic partner is. The price should now move into an uptrend with more news to come.

[don muang] 30/11/2007 08:01

.... well, personally, I like all of it (the RNS)..... leading global medical devices business ...... size of vital sign monitoring market ..... retain all the background IP....explore further revenue streams for the technology .... etc

[dalcon01] 30/11/2007 07:09

Like this bit............

Guy Spelman, Nanoscience's CEO, commented:

`This is the most significant landmark in the seven year history of Toumaz as the road to commercialisation is now visible and we look forward to reporting on further progress throughout 2008.'

[papalpower] 30/11/2007 07:03

Lovely news.

[dalcon01] 30/11/2007 07:01

Nanoscience Strategic Alliance

Embargoed Release: 07:00hrs Friday 30 November 2007

Nanoscience Inc.

(`Nanoscience' or the `Group')

Strategic Development and Distribution Alliance

Nanoscience is pleased to announce that its wholly owned subsidiary, Toumaz Technology Limited (`Toumaz'), has entered into a Strategic Development and Distribution Alliance (the `Alliance') with a leading global medical devices business (the `Strategic Partner'). Through the Alliance it is intended that the two parties will develop agreed solutions, incorporating Toumaz's Amx(tm) technology and its Sensium platform, that will be sold into global healthcare markets with the objective of becoming global leaders in handheld and body worn wireless diagnostic and monitoring products. It is envisaged that these next generation monitoring products will be disposable, non invasive and capable of providing real time critical vital sign information. From the inception of the Alliance Toumaz will receive funds from its Strategic Partner for further development work.

Furthermore, the Strategic Partner has committed to provide funding and resources to assist in gaining any necessary regulatory approvals and will carry out global manufacturing, product marketing, sales and distribution.

The Directors of Nanoscience estimate, on the basis of existing market data, that the vital sign monitoring market already exceeds $1.5bn and continues to grow, whilst the Point of Care diagnostics worldwide market is estimated at $10bn and growing.

Toumaz will retain all the background intellectual property relating to its AMx (tm) platform and will be entitled to explore further revenue streams for the technology outside of the field of use being exploited jointly with its Strategic Partner.

It is anticipated that ongoing success within the program will result in a growing financial and technical commitment from Toumaz's Strategic Partner and the Board look forward to reporting on further progress in the first half of next year.

Nanoscience has provided Toumaz with ongoing research and development funding and has continued to work closely alongside its management team to provide the additional commercial and corporate expertise that has resulted in the establishment of this landmark alliance.

Chris Toumazou, Chairman of Toumaz Technology Limited, commented:

`The establishment of this alliance is a very positive development for Toumaz, and we now have the opportunity to provide end to end solutions in the personalized healthcare space. This has been a key strategic goal of the business that we now believe is deliverable.'

Guy Spelman, Nanoscience's CEO, commented:

`This is the most significant landmark in the seven year history of Toumaz as the road to commercialisation is now visible and we look forward to reporting on further progress throughout 2008.'

-Ends-

Further information:

Guy Spelman Nanoscience Inc. 07767 338 967 Simon Raggett Strand Partners Limited 0207 409 3494 Matthew Chandler Andrew Tan Hansard Group 020 7245 1100 www.hansardgroup.co.uk

About Nanoscience Inc.:

Nanoscience is a specialist niche investor in emerging technologies with a strong commercial proposition from within the medical technology and semiconductor sectors.

About Toumaz (www.toumaz.com):

Toumaz, winner of the first prize at the fifth Oracle Partner Network (OPN) Innovation Awards for Europe, the Middle East and Africa and the IET Innovation Award for Electronics 2007 is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company's proprietary AMx(tm) (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.

END

[the drewster] 28/11/2007 20:44

I guess a lot of people were hoping for news of a deal or two by now, and getting impatient. Think my money is very safe here and will buy more if I feel the drop gets overdone.

[spekky] 28/11/2007 12:52

Yes it does n't take much to move it in either direction.
I think the next step in the Toumaz evolution is "Full approval under the European Medical Devices Directive and CE marking for the deployment of Sensium I in clinical trials by December 2007".
As with all things,that might not come on time,but it will definately be a significant step towards commercialising Sensium.CT also mentioned in his speech that they were expecting FDA approval soon and talked about rolling it out in US hospitals first.
We just need to be patient,2008 should be very rewarding.

[ilancas] 28/11/2007 11:56

Thanks spekky. I wonder why the drop this morning - just a marked down on a few sells I guess.

[spekky] 28/11/2007 09:44

If your one of those people who only do the occasional bit of research on your chosen share,then this should be the one its a MUST READ.



Pages 25-38 is a transcript of a speech on 29/10/07 at the royal academy of engineering by prof.Chris Toumazou.

AMAZING STUFF (even i can understand it).Look particularly at those companies he mentions.

[spekky] 26/11/2007 16:32

Thats one I missed in Sept. and is of interest to us because of this.extract from the final results.

"Future Waves' competitiveness is further
demonstrated via commercial relationships being developed with industry leaders
including Pure Digital, the UK market leader in digital radios and a wholly
owned subsidiary of Imagination Technologies plc, Sunplus Technology Co. Ltd.,
and Maxscend Technologies Inc. Fenix based products including GPS, MP3 and
digital radios are expected to be in the retail shops from summer 2007"

Where has Maxscend been flagged up to us as a licensee previously or did I miss that one too?



Possibly that is the one and the relationship has developed to the point where NAN are allowed to mention the company name now.